Format

Send to

Choose Destination
ACS Med Chem Lett. 2012 Mar 28;3(5):367-72. doi: 10.1021/ml3000066. eCollection 2012 May 10.

Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.

Author information

1
Departments of Medicinal Chemistry, Hypertension, Ion Channels, Preclinical DMPK, and Chemistry Modeling, Merck Research Laboratories , Rahway New Jersey 07065, United States.

Abstract

The renal outer medullary potassium channel (ROMK or Kir1.1) is a putative drug target for a novel class of diuretics that could be used for the treatment of hypertension and edematous states such as heart failure. An internal high-throughput screening campaign identified 1,4-bis(4-nitrophenethyl)piperazine (5) as a potent ROMK inhibitor. It is worth noting that this compound was identified as a minor impurity in a screening hit that was responsible for all of the initially observed ROMK activity. Structure-activity studies resulted in analogues with improved rat pharmacokinetic properties and selectivity over the hERG channel, providing tool compounds that can be used for in vivo pharmacological assessment. The featured ROMK inhibitors were also selective against other members of the inward rectifier family of potassium channels.

KEYWORDS:

KCNJ1; Kir; Kir1.1; ROMK; diuretics; hERG; heart failure; high-throughput screening (HTS); hypertension; inward rectifier; potassium channel

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center